All the management has done is get clinical trials completed for Brilacidin for ulcerative proctitis, ABSSSI, oral mucositis, developed a time-release formulation for ulcerative colitis, and made a deal with AlfaSigma; shepherded Kevetrin's cancer trials; and gotten Prurisol through clinical trials -- and all on a tiny budget. Only Prurisol did not pan out as expected. That is a much better track record than most companies.

But no, who would expect a soft-basher to respect the work of management, in the face of a concerted attack by a gang of short-sellers, whose minions have relentlessly bashed the company on message boards for years?

I wouldn't. The multi-identities continue their plan of trying to get people to believe they are actual investors, then bashing the company. We are not so stupid as to pay attention to the lies and misrepresentations of multi-identity posters who have hampered the ability of the company to get financing, and thus are responsible for the deaths of untold numbers of people who COULD have benefited from the company's incredibly promising drugs.

Blood on your hands, multi-identities.